Previously we have discussed neuropathy in the context of diabetic neuropathy, back-related neuropathies and the like. However, this week we are going to discuss an autoimmune neuropathy called ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

Investigational therapies may soon change the treatment landscape for chronic inflammatory demyelinating polyneuropathy (CIDP). "Despite the fact that we have some good standard-of-care therapies -- ...

Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct ...

PHOENIX -- A subcutaneous infusion of efgartigimod cut the risk of relapse in patients with a rare but serious immune-mediated neuropathy, according to the phase II ADHERE trial. Patients with ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme's Enhanze drug delivery ...

Credit: Getty Images. The SC formulation of efgartigimod alfa plus hyaluronidase-qvfc is currently marketed under the brand name Vyvgart Hytrulo for generalized myasthenia gravis. Treatment with the ...

Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.

VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ...